Discover insights into myeloid-origin cancers with a targeted DNA panel
Detect single nucleotide variants, insertions, deletions, copy number variations, and internal tandem duplications with targeted NGS of 75 genes relevant for acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and lymphoid malignancies research.
Detect confidently with Archer VARIANTPlex NGS Panels for DNA.
Learn how the VARIANTPlex Myeloid panel can identify key genomic alterations for your research.
Request a consultationSpecifications | |
---|---|
Targeted genes | 75 |
Genomic alterations | SNVs, Indels, CNVs, ITDs |
Input nucleic acid required* | ≥10 ng |
Recommended number of reads | 4 M |
Hands-on time | <3.5 hours |
Total library prep time | 1.5 days |
Platform compatibility | Illumina® |
Reagent format | Lyophilized or liquid |
Supported sample types | Blood, bone marrow, fresh frozen, BMMC, PBMC |
*Input mass requirements vary depending on type and quality. Unless the tumor cellularity and sample quality are high, 50 ng of FFPE-derived nucleic acid should be considered the minimum recommendation. If input is not limiting, 200 ng is recommended.
Customize this NGS panel by adding any of our functionally-tested designs or create a new panel that fits your exact requirements with Assay Marketplace.
Talk with our technical sales team. Learn how the VARIANTPlex Myeloid panel can identify key genomic alterations for your research.
Request a consultationRearrangements that involve BCR or TCR loci, (e.g. IGH, IGK, or IGL) often juxtaposes regulatory regions upstream of partner promoter regions which do not result in chimeric transcripts, instead leading to aberrant expression of the partner gene (e.g., MYC, BCL2, or BCL6). Fusions that do not produce chimeric transcripts cannot be detected using the RNA Fusion pipeline. To address this, we target the BCR and TCR, known partner genes for both fusion detection and relative RNA expression analysis.
For further information on identifying these types of rearrangements or our Relative RNA Expression pipeline, please contact our technical support team at archer-tech@idtdna.com.
Yes, DNA and RNA from a single sample can be analyzed with VARIANTPlex™ and FUSIONPlex™ panels to provide a genomic profile of the blood cancer. For comprehensive genomic profiling, pair FUSIONPlex Pan Heme and VARIANTPlex Myeloid panels to interrogate 226 genes for fusions, splicing, exon-skipping, SNVs, indels, CNVs, ITDs and expression levels. Additionally, IMMUNOVerse™ assays can provide T- and B-cell clonality, MRD, and somatic hypermutation information relevant for heme malignancies. IMMUNOVerse panels have parallel workflows with VARIANTPlex and FUSIONPlex assays, allowing for comprehensive, streamlined blood cancer profiling.
As opposed to traditional priming methods, AMP chemistry enables tiling primers across both strands of DNA, optimally covering targeted regions for amplification and characterization of challenging, yet relevant alterations such as internal tandem duplications. Additionally, AMP chemistry uses molecular barcode adapters that bind to DNA fragments before amplification, allowing for efficient amplification of targets even from degraded or fragmented nucleic acid input, such as DNA from FFPE tissue and ctDNA from plasma.
RUO23-2346_001